WO2009069448A1 - Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine - Google Patents
Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine Download PDFInfo
- Publication number
- WO2009069448A1 WO2009069448A1 PCT/JP2008/070282 JP2008070282W WO2009069448A1 WO 2009069448 A1 WO2009069448 A1 WO 2009069448A1 JP 2008070282 W JP2008070282 W JP 2008070282W WO 2009069448 A1 WO2009069448 A1 WO 2009069448A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- japanese
- nucleotides
- encephalitis vaccine
- length
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Disclosed is a Japanese B encephalitis vaccine containing, as an adjuvant, a novel immunostimulating oligonucleotide having an enhanced interferon (IFN)-inducing activity and a reduced inflammatory cytokine-inducing activity. Also disclosed is an adjuvant for a Japanese B encephalitis vaccine, which comprises an oligonucleotide that is represented by the formula: 5'-(G)MPXCGYQ(G)N-3' [wherein C represents a cytosine residue; G represents a guanine residue; X and Y independently represent a nucleotide sequence that has a length of 0 to 10 nucleotides and does not contain contiguous four or more guanine residues (provided that the total length of X and Y is 6 to 20 nucleotides); XCGY represents a nucleotide sequence that has a length of 8 to 22 nucleotides and contains a palindrome sequence having a length of at least 8 nucleotides; P and Q independently represent a nucleotide residue other than a guanine residue; M represents an integer of 6 to 10; and N represents an integer of 0 to 3], and that has the total length of 16 to 37 nucleotides (provide that an oligonucleotide comprising the nucleotide sequence depicted in SEQ ID NO:5 in the Sequence Listing is excluded).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007307932 | 2007-11-28 | ||
JP2007-307932 | 2007-11-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009069448A1 true WO2009069448A1 (en) | 2009-06-04 |
Family
ID=40678350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2008/070282 WO2009069448A1 (en) | 2007-11-28 | 2008-11-07 | Adjuvant for japanese b encephalitis vaccine, and japanese b encephalitis vaccine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009069448A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9764031B2 (en) | 2010-05-26 | 2017-09-19 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083076A1 (en) * | 2004-02-27 | 2005-09-09 | Emori & Co., Ltd. | Immune stimulant oligonucleotide inducing interferon alpha |
WO2006035939A1 (en) * | 2004-09-30 | 2006-04-06 | Osaka University | Immune stimulating oligonucleotide and use thereof in pharmaceutical |
WO2006108358A1 (en) * | 2005-04-13 | 2006-10-19 | Changchun Huapu Biotechnology Co., Ltd. | ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN |
-
2008
- 2008-11-07 WO PCT/JP2008/070282 patent/WO2009069448A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083076A1 (en) * | 2004-02-27 | 2005-09-09 | Emori & Co., Ltd. | Immune stimulant oligonucleotide inducing interferon alpha |
WO2006035939A1 (en) * | 2004-09-30 | 2006-04-06 | Osaka University | Immune stimulating oligonucleotide and use thereof in pharmaceutical |
WO2006108358A1 (en) * | 2005-04-13 | 2006-10-19 | Changchun Huapu Biotechnology Co., Ltd. | ANTIVIRAL USE OF ARTIFICIAL CpG-CONTAINING SINGLE-STRANDED OLIGODEOXYNUCLEOTIDES IN COMBINATION WITH RIBAVIRIN |
Non-Patent Citations (2)
Title |
---|
KAMSTRUP, S. ET AL.: "Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides", VET MICROBIOL, vol. 78, no. 4, 2001, pages 353 - 362 * |
YAMAMOTO, S. ET AL.: "Unique palindromic sequences in synthetic oligonucleotides are required to induce IFN [correction of INF] and augment IFN-mediated [correction of INF] natural killer activity", J IMMUNOL, vol. 148, no. 12, 1992, pages 4072 - 4076 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9764031B2 (en) | 2010-05-26 | 2017-09-19 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Unfried et al. | Nucleotide sequence of the 5.8 S and 25S rRNA genes and of the internal transcribed spacers from Arabidopsis thaliana. | |
WO2009061941A3 (en) | Baseless nucleotide analogues and uses thereof | |
JP2010519915A5 (en) | ||
WO2005108411A3 (en) | Substituted pixyl protecting groups for oligonucleotide synthesis | |
WO2008016909A3 (en) | Nucleotide analogs | |
WO2000061151A3 (en) | Oligodeoxynucleotide and its use to induce an immune response | |
RU2014117018A (en) | APTAMER AGAINST NGF AND ITS APPLICATION | |
NZ598943A (en) | Hbv antisense inhibitors | |
RU2014130600A (en) | ANTISONIC NUCLEIC ACIDS | |
WO2009006478A3 (en) | 6-disubstituted bicyclic nucleic acid analogs | |
NZ594429A (en) | Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease | |
WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
WO2002069903A3 (en) | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases | |
WO2003015798A1 (en) | Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue | |
NZ563845A (en) | RNAi sequences against the Influenza A segment 1 PB2 gene and uses thereof as anti-viral therapeutic | |
HUP0105367A2 (en) | Novel nucleosides and oligonucleotide analogues | |
MX2013003179A (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment. | |
WO2005007875A3 (en) | Enhanced promoters for synthesis of small hairpin rna | |
AU2008309264A8 (en) | Immune stimulatory oligonucleotide analogs containing modified sugar moieties | |
WO2007140506A8 (en) | Modified microbial nucleic acid for use in detection and analysis of microorganisms | |
EP3040423A3 (en) | Microrna and uses thereof | |
MXPA01010392A (en) | Production of attenuated negative stranded rna virus vaccines from cloned nucleotide sequences. | |
RU2012100248A (en) | APTAMER TO CHEMISTRY AND ITS APPLICATION | |
WO2007147067A3 (en) | Methods and compositions for regulating cell cycle progression | |
WO2010040033A4 (en) | Methods and compositions for modulating an immune response with immunogenic oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08853411 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08853411 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |